The European Food Safety Authority (EFSA) has stepped into the spotlight with a rapid risk assessment aimed at ensuring the safety of infants consuming formula milk. This move will certainly get the attention of infant formula manufacturers, health regulators across EU member states, consumer safety advocates, and parenting groups alike. The concern arose after traces of cereulide, a heat-stable toxin produced by Bacillus cereus and linked to vomiting, were detected in infant formulae, leading to precautionary recalls in several countries.
Published on 2 February 2026 by EFSA following a request from the European Commission, this scientific statement marks a swift response to a potential public health issue. EFSA's Food Additives and Contaminants Unit compiled this rapid risk assessment, relying on toxicological data and consumption patterns to deliver actionable conclusions.
This document is an official EFSA scientific statement rather than formal legislation. It presents concrete scientific evaluations including the derivation of an acute reference dose (ARfD) for cereulide for infants, based on benchmark dose modelling of emesis (vomiting) as the critical adverse effect. It also updates consumption data for infant formula and follow-on formulae to refine exposure estimates.
EFSA derived a benchmark dose lower confidence limit (BMDL10) of 4.2 micrograms per kilogram of body weight (μg/kg bw) linked to a 10% increased risk of emesis, based on an adult animal model. Applying uncertainty factors to account for infant vulnerability resulted in an ARfD of 0.014 μg/kg bw. EFSA confirmed a high consumption value of 260 mL/kg bw for infant formula and a P95 consumption value of 140 mL/kg bw for follow-on formula. Consequently, cereulide concentrations above 0.054 μg/L in infant formula and 0.1 μg/L in follow-on formulae may exceed the safety threshold.
This assessment increases the regulatory focus on controlling cereulide levels in infant food products to prevent acute toxicity risks, representing a move toward stricter chemical contaminant surveillance in the sector. Infant formula manufacturers face the challenge of ensuring compliance with these new exposure benchmarks, potentially prompting reformulation or more rigorous testing. National food safety authorities will need to incorporate these scientific recommendations into their monitoring and enforcement strategies. Parents and advocacy groups may feel reassured by the scrutiny but also vigilant about product safety. EFSA itself strengthens its role as a scientific risk assessor providing pivotal guidance to policymakers and stakeholders.
This statement is clearly a surge forward in the EU's food safety vigilance rather than an endpoint. It is the beginning of the implementation phase where regulatory bodies will interpret and act upon EFSA's modelled ARfD. The European Commission is expected to respond with regulatory proposals, and national authorities will have to reinforce surveillance accordingly. The food industry will be closely watching subsequent regulatory adjustments that might impose new technical or operational demands.
In sum, EFSA's rapid risk assessment plainly prioritizes acute consumer protection in infant nutrition by tightening the safety thresholds for cereulide, balancing concerns about chemical contaminant exposure against the practical impacts on industry and regulators.